Agenus (AGEN) Free Cash Flow (2010 - 2026)
Agenus (AGEN) posted quarterly Free Cash Flow of -$35.9 million for Q1 2026, down 40.3% year-over-year from -$60.2 million in Q1 2025, and down 116.33% quarter-over-quarter from -$16.6 million in Q4 2025.
Agenus (AGEN) Free Cash Flow (2010 - 2026) Analysis & Trends
Agenus' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$35.9 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 40.3% year-over-year to -$35.9 million; the TTM figure through Mar 2026 stood at -$87.5 million (up 40.17% YoY), while the FY2025 annual figure was -$77.2 million, up 51.41% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$35.9 million, down from -$16.6 million in the prior quarter.
- The five-year high for Free Cash Flow was -$14.7 million in Q3 2025, with the low at -$68.7 million in Q3 2023.
- The 5-year median for Free Cash Flow is -$38.6 million (2024), against an average of -$40.4 million.
- The sharpest annual moves came in 2023 and 2025: Free Cash Flow tumbled 127.56% in 2023, then jumped 72.35% in 2025.
- Agenus' Free Cash Flow stood at -$43.4 million in 2022, then advanced by 6.33% to -$40.6 million in 2023, then increased by 29.29% to -$28.7 million in 2024, then surged by 42.15% to -$16.6 million in 2025, then plunged by 116.33% to -$35.9 million in 2026.
- Business Quant data shows AGEN's Free Cash Flow at -$35.9 million in Q1 2026, -$16.6 million in Q4 2025, and -$14.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Agenus | 311.95 Mn | 286.43 Mn | 34.52 Mn | -31.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -31.20 Mn |
| Jun 30, 2026 | -31.20 Mn |
| Mar 31, 2026 | -35.95 Mn |
| Mar 31, 2026 | -35.95 Mn |
| Dec 31, 2025 | -16.62 Mn |
| Dec 31, 2025 | -16.62 Mn |
| Sep 30, 2025 | -14.74 Mn |
| Sep 30, 2025 | -14.74 Mn |
| Jun 30, 2025 | -20.22 Mn |
| Jun 30, 2025 | -20.22 Mn |
| Mar 31, 2025 | -25.62 Mn |
| Mar 31, 2025 | -25.62 Mn |
| Dec 31, 2024 | -28.73 Mn |
| Dec 31, 2024 | -28.73 Mn |
| Sep 30, 2024 | -53.30 Mn |
| Sep 30, 2024 | -53.30 Mn |
| Jun 30, 2024 | -38.64 Mn |
| Jun 30, 2024 | -38.64 Mn |
| Mar 31, 2024 | -38.23 Mn |
| Mar 31, 2024 | -38.23 Mn |